67614-32-8

Upstream product

• 51631-50-6 2-(4-chlorophenyl)-3-methyl-(2SR)-butanoyl chloride 
• 39515-47-4 (S)-m-phenoxybenzaldehyde cyanohydrin 
• 956498-38-7 α-cyano-3-phenoxybenzyl S-(+)-2-(4-chlorophenyl)isovalerate 
• 39515-51-0 3-Phenoxybenzaldehyde 
• 63640-09-5 (R)-2-(4-chlorophenyl)-3-methylbutyric acid 
• 2012-74-0 2-(4-chlorophenyl)-3-methylbutyric acid 
• 298702-31-5 (S)-(+)-cyano(3-phenoxyphenyl)methyl butyrate 
• 39515-47-4 2-hydroxy-2-(3-phenoxyphenyl)acetonitrile 
• 71697-10-4 (R)-4-chloro-α-(1-methylethyl)benzenecaetyl chloride 

Relevant academic research and scientific papers

Process for preparing (S)- alpha-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-isovalerate

The present invention relates to an environmentally benign process for the preparation of (S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)isovalerate from its diastereomeric mixture (RS)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl) isovalerate.

'Gelozymes' in organic synthesis. Part 2: Candida rugosa lipase mediated synthesis of enantiomerically pure (S)-cyano(3-phenoxyphenyl)methyl butyrate

Significant changes in enantioselectivity (E) have been observed when the butanoate ester of (±)-1-hydroxy-1-(3-phenoxyphenyl)acetonitrile was subjected to hydrolysis in acetate buffer (pH 4.5, E = 6.4) and alcoholysis with 1-butanol in hexane catalysed by Candida rugosa lipase (E = 45). Enantiomerically pure (S)-butanoate ester so obtained (e.e. 98.4%) was converted to the corresponding (S)-cyanohydrin using Pseudomonas cepacia (Amano Ps) gelozyme. This strategy overcomes the problem of separation of the unwanted (R)-ester from the (S)-cyanohydrin.

Development of an immunoassay for the pyrethroid insecticide esfenvalerate

A competitive enzyme-linked immunosorbent assay was developed for the detection of the pyrethroid insecticide esfenvalerate. Two haptens containing amine or propanoic acid groups on the terminal aromatic ring of the fenvalerate molecule were synthesized and coupled to carrier proteins as immunogens. Five antisera were produced and screened against eight different coating antigens. The assay that had the least interference and was the most sensitive for esfenvalerate was optimized and characterized. The I50 for esfenvalerate was 30 ± 6.2 μg/L, and the lower detection limit (LDL) was 3.0 2+ 1.8 μg/L. The assay was very selective. Other pyrethroid analogues and esfenvalerate metabolites tested did not cross-react significantly in this assay. To increase the sensitivity of the overall method, a C18 sorbent-based solid-phase extraction (SPE) was used for water matrix. With this SPE step, the LDL of the overall method for esfenvalerate was 0.1 μg/L in water samples.